Efficacy of levamisole with standard care treatment vs. standard care in clinical presentations of non-hospitalized patients with COVID-19: a randomized clinical trial

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

Asgardoon Mohammad Hossein; EMADI KOOCHAK HAMID; KAZEMI GALOUGAHI MOHAMMAD HASSAN; Zare Dehnavi Ali; Khodaei Behzad; Behkar Atefeh; DEHPOUR AHMAD REZA; KHALILI HOSSEIN; AMINIANFAR MOHAMMAD

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Frontiers in Emergency Medicine Year:2022 | Volume:6 | Issue:3 Page(s): 0-0

Download Full-Text

View:

Download:

Cites:

Information Journal Paper

Title

Efficacy of levamisole with standard care treatment vs. standard care in clinical presentations of non-hospitalized patients with COVID-19: a randomized clinical trial

Author(s)

Keywords

COVID-19

Levamisole

Randomized Controlled Trial

SARS-CoV-2

Signs and Symptoms

Abstract

Objective: The aim of this study was to evaluate the influence of adding a 10-day course of Levamisole (LVM) to the standard care compared with standard care alone, on the clinical status of COVID-19 patients with mild to moderate disease. Methods: In this randomized open-label trial, we enrolled non-hospitalized patients with mild to moderate COVID-19 at nine health centers in Tehran province, Iran, in 2021. Patients were randomly assigned to receive a 10-day course of LVM with standard care (n=185) or standard care alone (n=180) in a 1: 1 ratio. On days 1 to 10, LVM was administered orally at a dosage of 50 mg. The participants were called and followed on days 1, 3, 5, 7, 9, and 14. The measured parameters were general health condition, hospitalization rate, Signs and Symptoms, and adverse events. The generalized estimating equationsmodel was used for analysis. Results: Among 507 randomized patients, 473 patients started the experiment and received LVM plus standard care or received the standard care alone,385 patients included in the analysis,346 (98%) patients completed the trial. The median age of the patients was 40 years [IQR: 32-50. 75],and 201 (55. 1%) patiens were male. The mean age, sex ratio, and frequency of the underlying diseases of the patients in the two study groups had no statistically significant differences (P>0. 05). Compared to the control group, LVM improved the general health condition of the patients (B=-0. 635,95% CI:-0. 041,-0. 329,P<0. 001). Patients receiving LVM compared with standard care group had significantly lower odds of developing fever (OR=0. 260,95% CI: 0. 113, 0. 599,P=0. 002), chills (OR=0. 223,95% CI: 0. 076, 0. 648,P=0. 006), fatigue (OR=0. 576,95% CI: 0. 346, 0. 960,P=0. 034), and myalgia (OR=0. 544,95% CI: 0. 317, 0. 932,P=0. 027). No significant difference was observed in the rate of hospitalization. Although the intervention group had greater adverse effects than the control group, the difference was not statistically significant. Conclusion: Findings of this study suggest that LVMhas clinical benefits in improving patients’,health condition with mild to moderate COVID-19.

Multimedia

No record.

Cites

No record.

References

No record.

Cite

APA: Copy

Asgardoon, Mohammad Hossein, EMADI KOOCHAK, HAMID, KAZEMI GALOUGAHI, MOHAMMAD HASSAN, Zare Dehnavi, Ali, Khodaei, Behzad, Behkar, Atefeh, DEHPOUR, AHMAD REZA, KHALILI, HOSSEIN, & AMINIANFAR, MOHAMMAD. (2022). Efficacy of levamisole with standard care treatment vs. standard care in clinical presentations of non-hospitalized patients with COVID-19: a randomized clinical trial. (FRONTIERS IN EMERGENCY MEDICINE) ADVANCED JOURNAL OF EMERGENCY MEDICINE, 6(3), 0-0. SID. https://sid.ir/paper/1137229/en

Vancouver: Copy

Asgardoon Mohammad Hossein, EMADI KOOCHAK HAMID, KAZEMI GALOUGAHI MOHAMMAD HASSAN, Zare Dehnavi Ali, Khodaei Behzad, Behkar Atefeh, DEHPOUR AHMAD REZA, KHALILI HOSSEIN, AMINIANFAR MOHAMMAD. Efficacy of levamisole with standard care treatment vs. standard care in clinical presentations of non-hospitalized patients with COVID-19: a randomized clinical trial. (FRONTIERS IN EMERGENCY MEDICINE) ADVANCED JOURNAL OF EMERGENCY MEDICINE[Internet]. 2022;6(3):0-0. Available from: https://sid.ir/paper/1137229/en

IEEE: Copy

Mohammad Hossein Asgardoon, HAMID EMADI KOOCHAK, MOHAMMAD HASSAN KAZEMI GALOUGAHI, Ali Zare Dehnavi, Behzad Khodaei, Atefeh Behkar, AHMAD REZA DEHPOUR, HOSSEIN KHALILI, and MOHAMMAD AMINIANFAR, “Efficacy of levamisole with standard care treatment vs. standard care in clinical presentations of non-hospitalized patients with COVID-19: a randomized clinical trial,” (FRONTIERS IN EMERGENCY MEDICINE) ADVANCED JOURNAL OF EMERGENCY MEDICINE, vol. 6, no. 3, pp. 0–0, 2022, [Online]. Available: https://sid.ir/paper/1137229/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops